<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anesthesia for the patient with liver disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anesthesia for the patient with liver disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anesthesia for the patient with liver disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Randolph H Steadman, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Victor W Xia, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie B Jones, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2872184630"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with liver disease frequently require surgery, and are at increased risk of intraoperative complications and postoperative morbidity and mortality. This topic will discuss perioperative risk and anesthetic management of patients with liver disease.</p><p>Epidemiology, diagnosis and management of various forms of liver disease, and preoperative risk assessment for patients with liver disease, are discussed separately. (See  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease"</a>.)</p><p class="headingAnchor" id="H3569903556"><span class="h1">PREOPERATIVE EVALUATION AND OPTIMIZATION</span></p><p class="headingAnchor" id="H812451074"><span class="h2">Screening for liver disease</span><span class="headingEndMark"> — </span>The preoperative history and physical examination for any patient should include the risk factors, signs, and symptoms of liver disease. Routine screening with liver function tests (LFTs) is not recommended, due to its low yield and uncertain implications for patients with no known liver disease. (See  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'Screening for liver disease before surgery'</a>.)</p><p class="headingAnchor" id="H1599208908"><span class="h2">Preoperative evaluation for patients with known liver disease</span><span class="headingEndMark"> — </span>Prior to surgery, the etiology, duration, and severity of hepatic dysfunction should be determined. Risk stratification and optimization of medical status should be performed preoperatively for elective surgery.</p><p class="headingAnchor" id="H287327087"><span class="h3">Risk stratification</span><span class="headingEndMark"> — </span>A number of conditions are considered contraindications to elective surgery  (<a class="graphic graphic_table graphicRef64509" href="/d/graphic/64509.html" rel="external">table 1</a>), including acute liver failure (previously termed fulminant hepatic failure) and acute viral or alcoholic hepatitis. Patients with mild to moderate chronic liver disease without cirrhosis usually tolerate surgery well. (See  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'Obstructive jaundice'</a>.)</p><p class="headingAnchor" id="H3663871925"><span class="h4">Risk scores for patients with cirrhosis</span><span class="headingEndMark"> — </span>Several scoring systems have been developed to predict the risk of postoperative mortality in patients with cirrhosis.</p><p class="bulletIndent1"><span class="glyph">●</span>The Child-Pugh classification has been used to assess the risk of non-shunt operations in patients with cirrhosis. One to three points are assigned to each of five parameters (encephalopathy, ascites, bilirubin, albumin, and prothrombin time [PT] or international normalized ratio [INR]). Patients with a score of 5 or 6 have Child-Pugh class A cirrhosis (well-compensated cirrhosis), those with a score of 7 to 9 have Child-Pugh class B cirrhosis (significant functional compromise), and those with a score of 10 to 15 have Child-Pugh class C cirrhosis (decompensated cirrhosis). (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Child-Pugh classification'</a>.)</p><p></p><p class="bulletIndent1">In studies conducted over multiple decades, the Child-Pugh score has correlated with perioperative mortality and morbidity. (See  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'Child-Pugh classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Model for End-stage Liver Disease (MELD) score was developed to predict short-term survival in patients awaiting liver transplant. The MELD score is increasingly used in other settings, including prediction of perioperative mortality in patients with cirrhosis who undergo non-transplant surgery.(See  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'MELD score and Mayo risk score'</a>.)</p><p></p><p class="bulletIndent1">The MELD score is a continuous scale (with higher values representing more severe liver disease) based on a formula that assigns weights to the patient’s serum bilirubin, creatinine, and INR. Multiple studies have evaluated the use of the MELD score for predicting postoperative morbidity and mortality in patients with cirrhosis [<a href="#rid1">1-6</a>]. In general, a MELD score of 10 to 15 confers increased perioperative risk, and patients with MELD scores &gt;15 should not undergo elective surgery. (See  <a class="medical medical_review" href="/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>.)</p><p></p><p class="bulletIndent1">In 2016, the MELD score was modified to include serum sodium concentration and to recognize hyponatremia as an independent prognostic factor that was not included in the original MELD score [<a href="#rid7">7</a>]. Studies have shown that MELD-Na and MELD scores predict perioperative risk and 30 day mortality similarly [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)", section on 'MELD-Na score'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mayoclinic.org%2Fmedical-professionals%2Ftransplant-medicine%2Fcalculators%2Fpost-operative-mortality-risk-in-patients-with-cirrhosis%2Fitt-20434721&amp;token=KS03cn0CyaPjb3BDGDwwESu44lv0d5jWtUSAUuXHjscnZSww%2FwB0n1gMlZz9UowqGnMgFPVDkDaml6K%2BewePslkVVwvibFRrWuLqDLzA2SivZnxrLKRYwRbKskpc2wrYstTK75%2Fs3OeQQumnMMq27WB1XcxPdOkAVL9n9Kuu08I%3D&amp;TOPIC_ID=91242" target="_blank">Mayo Risk Score</a> is an online calculator designed to predict post-operative mortality in patients with cirrhosis, using the MELD parameters, age, American Society of Anesthesiologists (ASA) physical status classification, and etiology of liver disease (<a class="calc calc_professional" href="/d/html/16436.html" rel="external">calculator 1</a>). It is based upon single center data from nearly 800 patients published in 2007 [<a href="#rid2">2</a>]. In a validation study, it was found to overestimate mortality [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Veterans Outcomes and Costs Associated with Liver Disease-University of Pennsylvania Score (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.vocalpennscore.com%2F&amp;token=5CnMhehlb6qiSCK80v48RyWwVdqMrl51fKYz%2BnOjDGUxVYTpa1iZO5DGT2VGcWND&amp;TOPIC_ID=91242" target="_blank">VOCAL-Penn Risk Score</a>), was derived from data on nearly 3800 patients undergoing 4700 surgeries between 2008 and 2016 at 128 Veterans Affairs hospitals [<a href="#rid8">8</a>]. This score contains the elements of the Mayo Risk Score, plus surgery category (abdominal laparoscopic, abdominal open, abdominal wall, vascular, orthopedic and chest/cardiac), which improved the VOCAL-Penn model's discrimination versus the Mayo Risk Score (C-statistic 0.859 versus 0.766, respectively). (See  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'VOCAL-Penn score'</a>.)</p><p></p><p class="headingAnchor" id="H11424755"><span class="h4">Risk associated with type of surgery</span><span class="headingEndMark"> — </span>As the VOCAL-Penn Risk score illustrates, the location of the surgical procedure is an important risk factor for postoperative liver failure in patients with pre-existing liver disease. Cardiac surgery, abdominal surgery, and hepatic resection are all associated with increased postoperative mortality compared with more peripheral surgery, presumably due to greater reductions in hepatic blood flow. Less invasive approaches, such as laparoscopy rather than laparotomy, or endoscopic stenting or percutaneous biliary drainage rather than cholecystectomy, may reduce risk. (See  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'Cardiac surgery'</a> and  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'Hepatic resection'</a> and  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'Abdominal surgery'</a>.)</p><p></p><p class="headingAnchor" id="H3635581314"><span class="h3">Laboratory evaluation</span><span class="headingEndMark"> — </span>Preoperative laboratory testing for patients with liver disease should include those tests that are likely to impact management, including hemoglobin, white cell count, platelet count, electrolytes, glucose, blood urea nitrogen, creatinine, prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (aPTT), fibrinogen, transaminase levels (alanine aminotransferase [ALT], aspartate aminotransferase [AST]), bilirubin and albumin. Other blood tests may be indicated, based on patient comorbidities.</p><p>Imaging may be warranted if cholecystitis, primary or metastatic cancer, or hepatic injury is suspected. Volumetric studies are helpful for estimating the size of the remnant liver after liver resection.</p><p class="headingAnchor" id="H1996686673"><span class="h4">Liver function tests</span><span class="headingEndMark"> — </span>Liver biochemical and function tests are commonly called liver function tests (LFTs), though many of the tests are not direct measures of liver function, and these tests are not liver specific. LFTs include aminotransferases (most commonly ALT and AST), alkaline phosphatase, tests of synthetic function (ie, albumin and PT or INR), and bilirubin. (See  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a> and  <a class="medical medical_review" href="/d/html/3573.html" rel="external">"Overview of liver biochemical tests"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without known liver disease</strong> – Routine screening with LFTs is not recommended; regardless, these tests are sometimes performed preoperatively. If the results are less than twice the normal range, it is reasonable to repeat the abnormal tests to make sure they are not increasing. If the results are greater than twice the normal range, or increasing, elective surgery should be postponed and the patient should be evaluated further. (See  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'Patients in whom surgery is contraindicated'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with known liver disease</strong> – Serum aminotransferases are elevated in most liver diseases and in disorders that involve the liver (such as various infections, acute and chronic heart failure, and metastatic carcinoma). The highest elevations occur in disorders associated with extensive hepatocellular injury, such as acute viral hepatitis, ischemic hepatitis (shock liver), and acute drug- or toxin-induced liver injury, all of which are contraindications to elective surgery.</p><p></p><p class="bulletIndent1">Albumin, bilirubin, and PT are laboratory parameters included in the Child-Pugh classification of the severity of cirrhosis, and bilirubin, INR, sodium, and creatinine are parameters included in the MELD score. (See  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'Child-Pugh classification'</a> and  <a class="medical medical_review" href="/d/html/1234.html" rel="external">"Assessing surgical risk in patients with liver disease", section on 'MELD score and Mayo risk score'</a>.)</p><p></p><p class="headingAnchor" id="H591670191"><span class="h3">Other organ systems</span><span class="headingEndMark"> — </span>For patients with known liver disease, a comprehensive medical assessment should be performed, recognizing that nearly every organ system may be affected by liver disease, with implications for perioperative management. Preoperative optimization should be individualized and approached by a multidisciplinary team. There is little evidence to support specific goals for preoperative care for these patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Encephalopathy </strong>–<strong> </strong>Hepatic encephalopathy is a multifaceted disorder that may occur in chronic liver disease. Metabolic factors can contribute to encephalopathy, some of which may be modified by anesthetic management. Hypoxia, hypovolemia, alkalemia, hypoglycemia, hypokalemia, and hyponatremia can all precipitate hepatic encephalopathy, and should be avoided in patients with liver disease. Sedatives (particularly benzodiazepines) can exacerbate hepatic encephalopathy, and in addition, encephalopathic patients are particularly sensitive to sedatives and hypnotics. (See  <a class="medical medical_review" href="/d/html/1257.html" rel="external">"Hepatic encephalopathy: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/1237.html" rel="external">"Hepatic encephalopathy in adults: Clinical manifestations and diagnosis", section on 'Evaluation for precipitating causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic abnormalities </strong>–<strong> </strong>Patients with liver disease frequently have abnormalities in routine laboratory tests of coagulation, including prolongations of the PT, INR, and activated partial thromboplastin time (aPTT), along with thrombocytopenia and elevated D-dimer, especially when liver synthetic function is more significantly impaired and portal pressures are increased. However, these tests are very poor at predicting the risk of bleeding in individuals with liver disease because they only reflect changes in procoagulant factors. Diminished hepatic function has both procoagulant and anticoagulant effects, resulting in rebalanced hemostasis, hypo- or hypercoagulability. Perioperative coagulation management is discussed below and in other UpToDate topics (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Physiologic effects of hepatic dysfunction'</a> and  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Laboratory abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular disease</strong> – Cardiovascular complications are common in patients with liver disease and are a major risk factor for postoperative mortality and morbidity. Patients with cirrhosis typically have a hyperdynamic circulation with low systemic vascular resistance (SVR) and high cardiac output (CO). Cardiovascular abnormalities increase with worsening hepatic function, and up to 50 percent of patients with advanced cirrhosis have features of cardiac dysfunction. The term "cirrhotic cardiomyopathy" has been used to describe a condition including normal to increased cardiac output and contractility at rest, accompanied by a blunted response to pharmacologic, physiologic, or pathologic stress that may result in overt heart failure [<a href="#rid10">10,11</a>]. Perioperative intravenous (IV) fluids should be managed carefully to avoid volume overload.</p><p></p><p class="bulletIndent1">Patients with liver disease are as likely as age-matched controls to have coronary artery disease, but may not be symptomatic due to functional limitations associated with liver disease. Minimally invasive tests for coronary disease are commonly used to screen patients with two or more coronary risk factors. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Cirrhotic cardiomyopathy'</a>.)</p><p></p><p class="bulletIndent1">Some forms of liver disease, including nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD) [<a href="#rid12">12</a>] and hepatitis C [<a href="#rid13">13,14</a>] may be associated with an increased incidence of coronary artery disease and cardiac morbidity and mortality. (See  <a class="medical medical_review" href="/d/html/3676.html" rel="external">"Extrahepatic manifestations of hepatitis C virus infection", section on 'Cardiac and cardiovascular disease'</a>.)</p><p></p><p class="bulletIndent1">Primary prophylaxis for esophageal variceal bleeding often includes the use of beta blockers, which may predispose patients to perioperative hypotension, and limit the utility of <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> stress testing due to inability to reach target heart rates. (See  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis", section on 'Preventive strategies'</a> and  <a class="medical medical_review" href="/d/html/6615.html" rel="external">"Management of cardiac risk for noncardiac surgery", section on 'Beta blockers'</a>.)</p><p></p><p class="bulletIndent1">Patients with portal hypertension may develop portopulmonary hypertension (PPHTN). Thus, cirrhotic patients undergoing major surgery should be screened preoperatively with resting echocardiography. Severe PPHTN (ie, mean pulmonary artery pressure &gt;50 mmHg) is a contraindication for liver transplant, and transplant should be delayed until pulmonary hypertension is treated. These patients are at risk for right heart failure, and like other patients with pulmonary hypertension, are at increased risk of perioperative morbidity and mortality. (See  <a class="medical medical_review" href="/d/html/6917.html" rel="external">"Evaluation of perioperative pulmonary risk", section on 'Pulmonary hypertension'</a> and  <a class="medical medical_review" href="/d/html/8266.html" rel="external">"Portopulmonary hypertension", section on 'Liver transplantation'</a> and  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Surgical or periprocedural care'</a>.)</p><p></p><p class="bulletIndent1">Anesthetic management for patients with pulmonary hypertension is discussed separately. (See  <a class="medical medical_review" href="/d/html/99944.html" rel="external">"Anesthesia for adults with congenital heart disease undergoing noncardiac surgery", section on 'Pulmonary arterial hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary complications</strong> – Patients with ascites may develop shortness of breath, ventilation/perfusion mismatch, pleural effusion, and decreased lung capacity. Those with massive ascites may not tolerate lying supine for induction of anesthesia, or during procedures performed under monitored anesthesia care or regional anesthesia. Patients with encephalopathy are at increased risk for pulmonary aspiration.</p><p></p><p class="bulletIndent1">Patients with chronic liver disease and portal hypertension may develop hepatopulmonary syndrome (HPS). The pathogenic mechanisms for HPS have not been clearly delineated, but are thought to be due to intrapulmonary vascular dilatations (IPVDs). IPVDs cause hypoxemia mostly via ventilation-perfusion mismatch and oxygen diffusion limitation. The etiology and pathogenesis of HPS is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8248.html" rel="external">"Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis", section on 'Etiologies and pathogenesis'</a>.)</p><p></p><p class="bulletIndent1">Patients with mild to moderate HPS may be treated with supplemental oxygen, and may require high intraoperative inspired oxygen concentrations if they come to surgery. Patients with severe HPS are typically evaluated for liver transplant as transplantation improves HPS. (See  <a class="medical medical_review" href="/d/html/16175.html" rel="external">"Hepatopulmonary syndrome in adults: Natural history, treatment, and outcomes", section on 'Treatment and prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Portal hypertension </strong>–<strong> </strong>Many of the complications of cirrhosis are the result of portal hypertension, which can result in formation of varices, circulatory, functional and biochemical abnormalities, and ascites. During abdominal surgery, goals of fluid administration should be to decrease pressure in the portal system to reduce bleeding. (See <a class="local">'Hemodynamic management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal dysfunction</strong> — Liver disease can cause a progressive decline in renal function, characterized by retention of sodium and free water, renal hypoperfusion, and decreased glomerular filtration, which can lead to hepatorenal syndrome (HRS). Renal dysfunction is an important risk factor for mortality, and serum creatinine is one of the parameters in the MELD score. (See  <a class="medical medical_review" href="/d/html/2308.html" rel="external">"Hepatorenal syndrome"</a>.)</p><p></p><p class="bulletIndent1">Cirrhotic patients are also at high risk for more common causes of renal dysfunction, such as parenchymal renal disease, sepsis, nephrotoxicity, and hypovolemia. HRS is a diagnosis of exclusion, and other potentially treatable causes must be ruled out since therapies differ. Unlike these other etiologies for renal dysfunction, the use of potent vasoconstrictors (eg, <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> or <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>) may be beneficial for patients with liver disease related renal dysfunction or HRS. The perioperative management of liver disease related renal dysfunction includes monitoring urinary output, avoidance of hyperkalemia and acidosis, and limiting exposure to nephrotoxins such as aminoglycosides. (See  <a class="medical medical_review" href="/d/html/2308.html" rel="external">"Hepatorenal syndrome", section on 'Approach to therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrolyte abnormalities </strong>–<strong> </strong>Hyponatremia develops slowly in patients with cirrhosis and parallels the progression of the disease. In general, serum sodium should not be corrected in these patients unless the serum sodium drops below 120 mEq/L, or neurologic symptoms develop. If hyponatremia needs to be corrected, it should be corrected slowly to avoid central pontine myelinolysis. (See  <a class="medical medical_review" href="/d/html/2326.html" rel="external">"Hyponatremia in patients with cirrhosis", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/2317.html" rel="external">"Osmotic demyelination syndrome (ODS) and overly rapid correction of hyponatremia"</a>.)</p><p></p><p class="bulletIndent1">Hypokalemia and metabolic alkalosis can occur with liver disease, and may trigger or exacerbate hepatic encephalopathy (see  <a class="medical medical_review" href="/d/html/2326.html" rel="external">"Hyponatremia in patients with cirrhosis"</a>). Hypokalemia should be corrected preoperatively, and ventilation should be managed to achieve a normal end tidal CO<sub>2</sub>. (See <a class="local">'Ventilation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain</strong> – Pain is prevalent in patients with liver disease, and is chronic in over one-half of patients [<a href="#rid15">15</a>]; opioids are widely used in patients with liver disease [<a href="#rid16">16</a>]. Altered pharmacokinetics and pharmacodynamics in these patients may make pain management extremely challenging [<a href="#rid17">17</a>]. (See <a class="local">'Opioids'</a> below.)</p><p></p><p class="bulletIndent1">Abdominal pain is the most common complaint, and may be caused by ascites, hepatic capsular distension, and splenomegaly. A fibromyalgia-like syndrome, which is related to a pro-inflammatory state, can be found in patients with cirrhosis [<a href="#rid18">18</a>]. Pain-related sleep and mood disorders are also common in patients with liver disease.</p><p></p><p class="headingAnchor" id="H4949677"><span class="h1">PERIOPERATIVE COAGULATION MANAGEMENT</span><span class="headingEndMark"> — </span>Perioperative hemostatic management for patients with liver disease undergoing surgery should be individualized. The general approach to coagulation management in patients with liver disease includes correcting <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> deficiency, optimizing the platelet count and fibrinogen level, and avoiding the use of international normalized ratio (INR) values to guide therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administer </strong><strong>vitamin K</strong><strong> </strong>–<strong> </strong>In anticipation of surgery for patients with liver disease and abnormal hemostatic laboratory tests, we administer <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> for patients with suspected deficiency (eg, patients with poor nutrition, cirrhosis, cholestatic disease, antibiotic use). (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'General approach to managing bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet transfusion </strong>–<strong> </strong>In patients with microvascular bleeding, or anticipating moderate to high risk surgery or intervention, we usually transfuse platelets to achieve a platelet count ≥50,000/microL. Abnormalities in platelet number and function in liver disease are in part compensated for by increased levels of von Willebrand factor (vWF), a platelet adhesive protein, and by decreased levels of ADAMTS13, the VWF-cleaving protease. Thrombin generation is preserved with platelet counts exceeding 50,000/microL, making this value a practical target in the setting of invasive procedures [<a href="#rid19">19</a>]. In patients undergoing minimal risk procedures, platelet counts ≥20,000/microL are well tolerated. In patients undergoing major surgery in a closed space such as craniotomy, a high platelet count (&gt;100,000/microL) may be required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintain fibrinogen </strong>–<strong> </strong>Fibrinogen plays a central role in clot stabilization. Guidelines for management of patients with severe perioperative bleeding [<a href="#rid20">20,21</a>] and for patients with severe liver disease who undergo surgery [<a href="#rid22">22</a>] suggest maintaining the fibrinogen level 150 to 200 mg/dL [<a href="#rid20">20,23</a>]. In minimally invasive procedures including gastrointestinal and interventional radiological procedures, maintaining the fibrinogen level &gt;100 mg/dL is recommended. When fibrinogen is needed, either cryoprecipitate or <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a> is administered depended on availability and preference. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'General approach to managing bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid using fresh frozen plasma</strong> –<strong> </strong>Standard coagulation testing with prothrombin time (PT) or INR is of limited value in patients with advanced liver disease. We <strong>do not</strong> routinely administer fresh frozen plasma to correct the INR. In patients with portal hypertension, administration of fresh frozen plasma elevates portal pressures, which can worsen bleeding. Viscoelastic tests (thromboelastography [TEG] or rotational thromboelastometry [ROTEM]) may be more appropriate than PT, INR, and partial thromboplastin time (aPTT) since TEG and ROTEM measure clot formation and lysis including the kinetics of clot formation, clot strength, interaction between endogenous pro- and anti-coagulation components, fibrinolysis and to some extent, platelet function. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Physiologic effects of hepatic dysfunction'</a> and  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Laboratory abnormalities'</a>.)</p><p></p><p class="headingAnchor" id="H943655830"><span class="h1">MANAGEMENT OF ANESTHESIA</span></p><p class="headingAnchor" id="H1164895373"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>In addition to standard anesthesia monitors, we have a low threshold for placing an intraarterial catheter for patients with severe liver disease to allow continuous blood pressure monitoring, and to facilitate blood sampling. The decision is based on the severity of liver disease and systemic vasodilation, coexisting diseases of other organ systems, the type and duration of surgery, anticipated intraoperative blood loss, the need for intraoperative laboratory studies, and patient age.</p><p>The usefulness of central venous pressure (CVP) monitoring is controversial [<a href="#rid24">24</a>], and many clinicians have abandoned CVP monitoring in the setting of liver resection [<a href="#rid25">25</a>]. In our practice, we do not place a central venous catheter (CVC) exclusively for pressure monitoring, but may place a CVC for venous access, or for vasopressor administration.</p><p>Transesophageal echocardiography (TEE) is a sensitive cardiac monitor, but placement of the TEE probe may be of concern in patients with esophageal varices and coagulopathy, and the use of TEE in these patients should be individualized. However, the risk of complications and esophageal hemorrhage in patients with severe liver disease appears to be low. In two large retrospective studies of TEE use during liver transplant, the incidence of major gastroesophageal injury was &lt;0.86 percent [<a href="#rid26">26,27</a>]. In a small series of patients with esophageal varices, TEE universally aided in diagnosis and was not associated with bleeding complications, although transgastric views were avoided to minimize esophageal manipulation [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H1881900285"><span class="h2">Choice of anesthetic technique</span><span class="headingEndMark"> — </span>The choice of anesthetic technique for patients with liver disease should be based on the surgical procedure and patient factors, similar to patients without liver disease. Neuraxial anesthesia, general anesthesia, and monitored anesthesia care may be options. Specific concerns include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Neuraxial anesthesia (ie, spinal or epidural) can cause systemic hypotension and reduced hepatic blood flow as a result of neuraxial block induced sympathectomy. Intravenous (IV) fluids and vasopressors are commonly administered to reverse such hypotension, but the literature on the effectiveness of vasopressors on hepatic blood flow in this setting is conflicting [<a href="#rid29">29-31</a>]. High thoracic neuraxial block (ie, T5) may reduce hepatic blood flow, and this effect may not be reversed with vasopressors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuraxial anesthesia procedures are contraindicated in patients with severe coagulopathy and/or thrombocytopenia because of increased risk of spinal epidural hematoma.</p><p></p><p class="bulletIndent1">Hepatic resection can cause new postoperative coagulopathy. Removal of an epidural catheter placed for postoperative pain control may cause epidural blood vessel injury and spinal epidural hematoma. The catheter should not be removed unless the platelet count and coagulation studies are at a level that would allow neuraxial needle insertion.</p><p></p><p class="bulletIndent1">The precise laboratory values and platelet count necessary to safely perform neuraxial anesthesia is unknown, and practice varies. The decision to perform peripheral nerve blocks in patients with coagulopathy should be individualized; bleeding complications may occur [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/397.html" rel="external">"Overview of peripheral nerve blocks", section on 'Contraindications'</a>.)</p><p></p><p class="headingAnchor" id="H1123655621"><span class="h2">Effects of anesthetics on the liver</span><span class="headingEndMark"> — </span>Anesthetic medications can affect the liver by influencing hepatic blood flow and/or by producing hepatotoxic byproducts. Drugs with high extraction ratios are significantly affected by alteration in hepatic blood flow, which can occur with hemodynamic changes or hepatic inflow clamping during liver resection.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Volatile anesthetics </strong>–<strong> </strong>Halothane, which is used outside the United States, should not be used for patients with liver disease.</p><p></p><p class="bulletIndent1">The other currently used volatile anesthetics (ie, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, and <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>) may reduce hepatic blood flow, but are not associated with hepatic toxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodynamic effects</strong> – All volatile anesthetics decrease hepatic blood flow (HBF) to a degree. <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">Isoflurane</a> and <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> result in very little reduction of hepatic blood flow at 1 minimum alveolar concentration (MAC) [<a href="#rid33">33</a>], though at higher doses, isoflurane causes a dose dependent reduction in HBF. <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">Desflurane</a> can decrease HBF by 30 percent at 1 MAC [<a href="#rid34">34</a>]. Halothane (no longer used in the United States) produces a greater reduction in cardiac output (CO) and hepatic oxygen supply than the other volatile anesthetics [<a href="#rid35">35</a>]. The degree to which these hemodynamic changes take place in patients with advanced liver disease has not been well studied.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatotoxicity </strong>–<strong> </strong>As a general rule, the degree of hepatic metabolism of anesthetic agents correlates with the likelihood of a toxic reaction. Of the haloalkanes used in practice, halothane (available outside the United States) has been associated with the greatest risk of hepatotoxicity, including acute, severe hepatitis, "halothane hepatitis." Halothane hepatitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Disadvantages and adverse effects'</a>.)</p><p></p><p class="bulletIndent2">The newer anesthetics, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> and <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, undergo less metabolism to trifluoroacetyl chloride (TFA), which is thought to be involved in halothane hepatic toxicity, than halothane (20 percent for halothane, 0.2 percent for isoflurane, and 0.02 percent for desflurane) [<a href="#rid36">36</a>]. Hepatic injury is extremely rare, if it exists, with isoflurane and desflurane. <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> does not undergo metabolism to TFA and has not been associated with immune mediated hepatic injury.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> metabolism produces fluoride and hexafluoroisopropanol (HFIP), which are conjugated by the liver and excreted by the kidney. There is no evidence that these metabolites or compound A, another metabolite produced in a reaction with carbon dioxide (CO<sub>2</sub>) absorbents, cause hepatic injury [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitrous oxide</strong><strong> (N</strong><strong><sub>2</sub></strong><strong>O)</strong> –<strong> </strong>N<sub>2</sub>O is not known to cause liver injury, though it may decrease hepatic blood flow mostly by sympathetic stimulation [<a href="#rid38">38</a>]. N<sub>2</sub>O can inhibit methionine synthase even after brief exposure, though the clinical significance of these effects in healthy patients is not clear [<a href="#rid39">39</a>]. Patients with vitamin B12 deficiency, such as some patients with cirrhosis, may be at increased risk for neurotoxicity with exposure to N<sub>2</sub>O [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/d/html/96308.html" rel="external">"Maintenance of general anesthesia: Overview", section on 'Nitrous oxide gas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV anesthetics </strong>–<strong> </strong>IV anesthetics (eg, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a>), when used for induction of anesthesia or for short procedures, do not appear to affect liver function, as long as CO and blood pressure (BP) are maintained.</p><p></p><p class="headingAnchor" id="H1048026661"><span class="h2">Effects of liver disease on anesthetic drug administration</span><span class="headingEndMark"> — </span>Liver disease can affect the pharmacokinetics of anesthetic drugs by changing drug metabolism, protein binding, and volume of distribution. In addition, efficiency of drug removal can be limited by reduction in hepatic blood flow due to portocaval shunting, hemodynamic changes, or reduced hepatic inflow during liver resection.</p><p></p><p>Selection of drugs and dose adjustments depend on the severity of liver disease. Patients with mild liver disease can usually be treated with a similar choice of drugs as those who are otherwise healthy. Susceptibility to adverse effects increases with worsening liver function due to altered pharmacokinetics and hemodynamic changes. Modifications (eg, dose reduction, titration to effect) should be considered for patients who have developed advanced chronic liver disease (eg, bridging fibrosis on biopsy) or cirrhosis, particularly when accompanied by portal hypertension (such as those with esophageal varices, ascites, or portal gastropathy/colopathy) or renal insufficiency.</p><p>In general, metabolism of drugs with high liver extraction ratios (eg, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">meperidine</a>) is affected by reduction in hepatic blood flow. Metabolism of drugs with low extraction ratios (eg, <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a>) is affected more by protein binding and hepatocellular dysfunction.</p><p class="headingAnchor" id="H2437853593"><span class="h3">Sedative hypnotics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction agents </strong>–<strong> </strong>In clinical practice, clearance of standard induction doses of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, thiopental (outside the United States), <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, <a class="drug drug_general" data-topicid="9629" href="/d/drug information/9629.html" rel="external">methohexital</a>, and <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> are similar in patients with liver disease and healthy patients [<a href="#rid42">42-45</a>]. Patients with liver disease are more sensitive to the pharmacodynamic effects of induction agents, and clinical recovery times may be prolonged after discontinuation of propofol infusions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benzodiazepines </strong>– Benzodiazepines are medications with low extraction ratios. Both elimination half-life and free drug are increased in patients with severe liver disease. Enhanced sedation and prolonged duration of action should be anticipated, especially with repeat doses. Reduced doses of <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> should be administered, and titrated to effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dexmedetomidine</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">Dexmedetomidine</a> is metabolized primarily in the liver. As a result, clearance is decreased, and half-life of elimination may be prolonged in patients with severe liver disease. Dosing may be limited by bradycardia. Although dexmedetomidine may be associated with decreased delirium and duration of mechanical ventilation, it has not been studied extensively in liver disease patients [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H1749919800"><span class="h3">Opioids</span><span class="headingEndMark"> — </span>Metabolism of opioids is reduced in patients with liver disease, and dosing intervals should be increased to avoid drug accumulation. The elimination of a single IV opioid bolus is less affected than a continuous infusion because of bolus redistribution to storage sites. Modifications of analgesics and pharmacokinetic changes in liver disease are shown in a table  (<a class="graphic graphic_table graphicRef90196" href="/d/graphic/90196.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fentanyl</strong><strong> </strong>–<strong> </strong>Elimination of a bolus dose of <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> is not appreciably altered in patients with cirrhosis [<a href="#rid47">47</a>], though with repeat administration or infusion, prolonged effects can occur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphine</strong><strong> </strong>–<strong> </strong>Clearance of <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> may be delayed by 35 to 60 percent in patients with cirrhosis [<a href="#rid47">47</a>]. Morphine should be titrated to effect, with the dose and frequency reduced by 50 percent in patients with severe liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydromorphone</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">Hydromorphone</a> is metabolized by the liver. Elimination is impaired and the half-life is prolonged in patients with advanced chronic liver disease or cirrhosis. Hydromorphone should be administered in reduced doses, titrated to effect, at increased dosing intervals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meperidine</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">Meperidine</a> should be avoided for patients with cirrhosis or advanced chronic liver disease. The plasma clearance of both meperidine and its neurotoxic metabolite, normeperidine, are reduced after a single IV dose [<a href="#rid48">48,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remifentanil</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">Remifentanil</a> is rapidly hydrolyzed by blood and tissue esterases. The clearance and elimination and recovery from the effects of remifentanil are unchanged in patients with severe liver disease [<a href="#rid50">50,51</a>].</p><p></p><p class="headingAnchor" id="H312141790"><span class="h3">Other analgesics</span><span class="headingEndMark"> — </span>The strategy for perioperative pain control usually incorporates a multimodal opioid sparing approach that may include <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, antidepressants, and anticonvulsants. Acetaminophen doses of 2 g/day are generally considered safe in patients with liver disease. For short-term use, acetaminophen up to 4 g/day in low risk patients and 2-3 g/day in high risk patients may be considered. Nonsteroidal antiinflammatory drugs (NSAIDs) are considered less safe due to their renal toxicity and bleeding risk [<a href="#rid15">15</a>], optimal choice of drugs and dose in the surgical setting is not known. Administration of such medications in patients with liver disease in the nonsurgical setting is discussed separately and in a table  (<a class="graphic graphic_table graphicRef90196" href="/d/graphic/90196.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/1236.html" rel="external">"Management of pain in patients with advanced chronic liver disease or cirrhosis"</a>.)</p><p class="headingAnchor" id="H1376578767"><span class="h3">Neuromuscular blocking agents</span><span class="headingEndMark"> — </span>Liver disease may affect the onset, metabolism, and duration of action of neuromuscular blocking agents (NMBAs). NMBAs should be titrated to effect, and administration should be guided by monitoring with a peripheral nerve stimulator. The reversal agent <a class="drug drug_general" data-topicid="105866" href="/d/drug information/105866.html" rel="external">sugammadex</a> is excreted in the urine unchanged, and there is concern about the possible recurrence of neuromuscular blockade in patients with end-stage kidney disease that may accompany severe liver disease. However, a multicenter retrospective review of 158 surgical patients with end-stage kidney disease who received sugammadex reversal reported no cases of recurrence of neuromuscular blockade [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Sugammadex'</a> and  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Succinylcholine</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">Succinylcholine</a> is metabolized by plasma cholinesterase, an enzyme that may be reduced in patients with advanced liver disease. The duration of action of succinylcholine may be prolonged in such patients [<a href="#rid53">53,54</a>], though this is rarely of clinical significance. Mivacurium (no longer available in the United States or Canada) is also metabolized by plasma cholinesterase, and neuromuscular block may be prolonged in patients with advanced liver disease [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rocuronium</strong><strong> and </strong><strong>vecuronium</strong><strong> </strong>–<strong> </strong>Both <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> and <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> are metabolized by the liver. Clearance, elimination, and duration of neuromuscular block are prolonged in patients with advanced liver disease [<a href="#rid57">57,58</a>]. Despite these changes, resistance to the initial dose of NMBA typically occurs due to elevated gamma-globulin concentrations and an increase in the volume of distribution (due to edema and/or ascites).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atracurium</strong><strong> and </strong><strong>cisatracurium</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">Atracurium</a> and <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a> undergo organ-independent elimination, and their elimination half-life and duration of action are not affected by liver disease [<a href="#rid59">59,60</a>].</p><p></p><p class="headingAnchor" id="H4186537116"><span class="h2">Hemodynamic management</span><span class="headingEndMark"> — </span>Goals for hemodynamic management for patients with liver disease include maintenance of hepatic perfusion, and for patients who undergo abdominal surgery, decreasing portal pressure to minimize bleeding.</p><p class="headingAnchor" id="H387691419"><span class="h3">Goal blood pressure</span><span class="headingEndMark"> — </span>The goal BP during induction and maintenance of anesthesia should be the patient's baseline. Many patients with liver disease have hyperdynamic circulation, characterized by low systemic vascular resistance (SVR), borderline hypotension, and elevated CO. These patients frequently require vasopressor support to avoid hypotension during induction and maintenance of anesthesia.</p><p class="headingAnchor" id="H2665581657"><span class="h3">Vasopressors</span><span class="headingEndMark"> — </span>Patients with liver disease have complex circulatory abnormalities including autonomic dysfunction and reduced responsiveness to vasoconstrictors (ie, angiotensin 2, <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a>, and <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>) [<a href="#rid61">61</a>]. In addition, patients with severe liver disease may be depleted of endogenous vasopressin [<a href="#rid62">62</a>]. These patients may require higher doses of the vasopressors that are usually administered during anesthesia (eg, <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a> or <a class="drug drug_general" data-topicid="9114" href="/d/drug information/9114.html" rel="external">ephedrine</a>). Norepinephrine and/or vasopressin may be required for BP support.</p><p class="headingAnchor" id="H2821989033"><span class="h3">Intravenous fluids</span><span class="headingEndMark"> — </span>In patients undergoing abdominal surgery, fluid restriction should be considered, with or without CVP monitoring, in order to lower portal pressures and reduce bleeding. In chronic liver disease, serum albumin function is quantitatively and qualitatively decreased [<a href="#rid63">63</a>]. We use albumin rather than crystalloid for perioperative volume expansion in liver disease patients with ascites or hypoalbuminemia to minimize postoperative edema. Specific indications for albumin include intravascular volume expansion after large-volume (4 to 5 L) paracentesis, in the presence of spontaneous bacterial peritonitis to prevent worsening renal impairment, and in conjunction with splanchnic vasoconstrictors for type 1 hepatorenal syndrome [<a href="#rid64">64-66</a>].</p><p>The threshold for red blood cell transfusion for patients with liver disease should be similar to the threshold for other patients, while considering the rate of bleeding and comorbidities (eg, cardiovascular disease).</p><p class="headingAnchor" id="H1394998788"><span class="h2">Ventilation</span><span class="headingEndMark"> — </span>Lung protective ventilation strategy (low tidal volume with PEEP and intermittent lung volume recruitment) is advocated for all patients by some investigators, and by this author. (See  <a class="medical medical_review" href="/d/html/93386.html" rel="external">"Mechanical ventilation during anesthesia in adults", section on 'Lung protective ventilation during anesthesia'</a>.)</p><p>Hypoxemia in liver disease patients may be related to ascites, pleural effusion, or atelectasis secondary to these conditions.</p><p class="headingAnchor" id="H3343029425"><span class="h2">Coagulation management</span><span class="headingEndMark"> — </span>Intraoperative coagulation management is discussed above. (See <a class="local">'Perioperative coagulation management'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.)</p><p></p><p class="headingAnchor" id="H245394329"><span class="h2">Postoperative care</span><span class="headingEndMark"> — </span>Patients with severe liver disease, significant comorbidities, or extensive intraoperative blood loss may require postoperative intensive care. Opioids and sedatives should be used cautiously in the postoperative period. IV fluids should be managed carefully to avoid ascites, edema, and/or heart failure [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H849685360"><span class="h2">Postoperative liver abnormalities</span><span class="headingEndMark"> — </span>Mild elevations of liver enzymes (ie, less than twice normal) occur frequently after surgery, particularly after upper abdominal procedures. When such mild elevations occur, the tests should be repeated; increases are typically transient and of no clinical consequence. The newer volatile anesthetic agents rarely cause postoperative elevations of liver function tests (LFTs) [<a href="#rid68">68,69</a>].</p><p>LFT elevations more than twice normal suggest hepatocellular injury, which can be the result of hypoxemia, viral or bacterial insult, trauma, or chemical toxicity.</p><p>Postoperative jaundice is commonly caused by reabsorption of surgical or traumatic hematomas, or red blood cell transfusion. Massive intraoperative blood transfusion results in a large bilirubin load, which may overwhelm the liver.</p><p class="headingAnchor" id="H2640527372"><span class="h1">ANESTHESIA FOR HEPATIC RESECTION</span><span class="headingEndMark"> — </span>Open or laparoscopic liver resection may be performed for a variety of indications, including benign or malignant lesions and donation for transplant. (See  <a class="medical medical_review" href="/d/html/15094.html" rel="external">"Overview of hepatic resection"</a>.)</p><p>Hepatic resection is performed with general anesthesia. Important issues for anesthesia for hepatic resection are discussed here.</p><p class="headingAnchor" id="H2853526563"><span class="h2">Hemorrhage</span><span class="headingEndMark"> — </span>There is always potential for sudden, rapid hemorrhage during hepatic resection, though a minority of patients require transfusion [<a href="#rid70">70,71</a>]. Blood loss depends partially on the extent of surgery; since the right lobe usually represents two-thirds of the liver mass, right lobe resection is associated with more extensive liver transection, blood loss, and alterations in clotting factor synthesis. A preoperative blood type and screen should be performed. We usually crossmatch 2 to 4 units of packed red blood cells prior to the start of surgery.</p><p>We place two large-bore (18 or 16 gauge) intravenous (IV) catheters. We also place an intraarterial catheter for continuous blood pressure (BP) monitoring, and to facilitate blood sampling, for most patients who undergo hepatic resection. Additional monitoring is dictated by the patient's medical status.</p><p>Intraoperative cell salvage can be considered in patients at high risk of bleeding, though its use is controversial in cases of primary or metastatic malignancy [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a>.)</p><p class="headingAnchor" id="H1319535712"><span class="h2">Low central venous pressure anesthesia</span><span class="headingEndMark"> — </span>We aim for euvolemia or mild hypovolemia, and avoid hypervolemia during hepatic resection. IV fluid management during hepatic resection is controversial. A strategy of restrictive fluid administration (with or without administration of vasodilators and/or diuretics), referred to as "low central venous pressure (CVP) anesthesia," has been suggested during these procedures to reduce blood loss. The goal is to lower the CVP during hepatic resection to reduce the pressure in hepatic and portal veins and the vena cava, which are often the sites of bleeding. In most studies, a CVP &lt;5 cm H<sub>2</sub>O is used to define low CVP anesthesia, though CVCs are now rarely used intraoperatively to monitor volume status. (See  <a class="medical medical_review" href="/d/html/14942.html" rel="external">"Intraoperative fluid management", section on 'Traditional static parameters'</a>.)</p><p>The value and necessity of CVP monitoring and low CVP management in this setting are debated. Retrospective reviews of living related donor hepatectomies have reported that CVP monitoring did not reduce blood loss [<a href="#rid25">25</a>], and that blood loss did not correlate with CVP level [<a href="#rid73">73,74</a>]. However, a meta-analysis of 18 randomized trials including 1285 patients found that blood loss and transfusion were less with low CVP management for hepatectomy, compared with standard management [<a href="#rid75">75</a>].</p><p>The optimal methods for achieving a low CVP (eg, fluid restriction, vasodilators, diuretics) and the optimal goal CVP are not clear. The head-up position should not be used to reduce CVP, as the hepatic vein pressure does not change [<a href="#rid76">76</a>], and the head-up position may increase the risk of venous air embolism with a low CVP.</p><p class="headingAnchor" id="H2953732945"><span class="h2">Pringle maneuver</span><span class="headingEndMark"> — </span>The vascular inflow to the liver may be interrupted during hepatic transection to prevent or control bleeding. The Pringle maneuver typically consists of intermittent clamping of the hepatic artery and portal vein for periods of 15 to 20 minutes; however, prolonged clamping exceeding 120 minutes has been tolerated [<a href="#rid77">77</a>]. Total vascular exclusion, in which the venous outflow of the liver is occluded in addition to the inflow vessels, is advantageous for minimizing bleeding in resections involving hepatic veins and the inferior vena cava [<a href="#rid78">78</a>]. These maneuvers have the potential to decrease venous return and cardiac output.</p><p class="headingAnchor" id="H2259092271"><span class="h2">Coagulopathy and epidural analgesia</span><span class="headingEndMark"> — </span>Even patients with normal preoperative coagulation can develop coagulopathy after liver resection, with implications for neuraxial analgesic procedures. (See  <a class="medical medical_review" href="/d/html/15094.html" rel="external">"Overview of hepatic resection", section on 'Coagulopathy and hemorrhage'</a>.)</p><p>The severity of postoperative coagulopathy correlates with the extent of the resection, peaks on postoperative day 1 to 2, and may take up to five or more days to resolve [<a href="#rid79">79,80</a>]. For patients who have an epidural catheter placed for postoperative pain control after open hepatic resection, the catheter should not be removed while clotting parameters are abnormal. Catheter removal may cause epidural blood vessel injury and spinal epidural hematoma. At our center, we offer epidural analgesia for postoperative management when the future liver remnant is ≥60 to 70 percent of total liver volume, realizing that the extent of resection may change intraoperatively based upon intraoperative ultrasound.</p><p>Alternatives to epidural analgesia for postoperative pain control include intrathecal opioids, single-shot or continuous peripheral nerve blocks and fascial plane blocks [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/d/html/105456.html" rel="external">"Spinal anesthesia: Technique", section on 'Adjuvants'</a> and  <a class="medical medical_review" href="/d/html/89518.html" rel="external">"Epidural and combined spinal-epidural anesthesia: Techniques", section on 'Opioids'</a> and  <a class="medical medical_review" href="/d/html/121447.html" rel="external">"Abdominal nerve block techniques"</a>.)</p><p class="headingAnchor" id="H3210124921"><span class="h1">ANESTHESIA FOR TRANSHEPATIC PORTOSYSTEMIC SHUNT</span><span class="headingEndMark"> — </span>Transhepatic portosystemic shunt (TIPS) is a percutaneous angiographic procedure that creates a shunt between the hepatic vein and the intrahepatic portal vein to decompress the portal system. After an internal jugular vein puncture, a needle catheter is passed through the vena cava into the hepatic vein. The needle is extruded and passed through the liver parenchyma to the portal vein. Accessing the portal vein may require multiple attempts, and the procedure may take several hours. (See  <a class="medical medical_review" href="/d/html/15233.html" rel="external">"Comparison of methods for endovenous ablation for chronic venous disease"</a>.)</p><p>TIPS may be performed with monitored anesthesia care, or with general anesthesia. General anesthesia is preferred for patients who would rather be asleep, and for those who are unable to tolerate the supine position for the duration of the procedure. Since TIPS worsens encephalopathy, most patient who are scheduled for TIPS do not have significant encephalopathy. However, for patients with altered mental status, general anesthesia with endotracheal intubation may be preferred to reduce the risk of aspiration.</p><p>Important considerations for anesthesia include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>TIPS is usually performed for patients with severe or end stage liver disease, often with massive ascites. (See  <a class="medical medical_review" href="/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p></p><p class="bulletIndent1">They may be unable to tolerate lying flat, and are at risk for aspiration with induction of anesthesia or with sedation at a depth that compromises airway protective reflexes. For general anesthesia, rapid sequence induction and intubation is usually indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>These procedures are performed in the angiography suite, and the head of the operating table may be turned away from the anesthesiologist. Access to the airway is limited, with the face under sterile drapes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulopathy should be assessed and corrected before the procedure. Goals should be a platelet count &gt;50,000/microL and fibrinogen &gt;150 to 200 mg/dL, without attempts to correct the INR. Viscoelastic testing (ie, thromboelastography or thromboelastometry) may be used to guide therapy, if available. A blood type and screen should be performed prior to TIPS. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'General approach to invasive procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Volume resuscitation may be required prior to TIPS for patients who have had variceal hemorrhage. If large volume paracentesis (ie &gt;5 L ascites removed) is performed prior to the procedure to facilitate portal vein puncture, albumin should be administered, rather than crystalloid, for IV volume repletion. (See  <a class="medical medical_review" href="/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy", section on 'Large-volume paracentesis'</a>.)</p><p></p><p class="bulletIndent1">Either 5 percent or 25 percent albumin may administered. Twenty five percent albumin is preferred for patients with significant hyponatremia (ie, serum sodium &lt;130), which is common in this patient population, since it contains less sodium than 5 percent albumin. This helps avoid a rapid rise in serum sodium, which is associated with osmotic demyelination syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immediate, intra-procedure complications of TIPS include vascular injury, hemorrhage, pneumothorax, and dysrhythmia. (See  <a class="medical medical_review" href="/d/html/1251.html" rel="external">"Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TIPS creates a rapid increase in venous return to the heart and can unmask previously undiagnosed cardiac dysfunction or pulmonary hypertension. Rapid hemodynamic deterioration, during the procedure or in the immediate postoperative period, is unusual, but may occur. (See  <a class="medical medical_review" href="/d/html/1251.html" rel="external">"Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications", section on 'Cardiac failure'</a>.)</p><p></p><p class="headingAnchor" id="H565765097"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative evaluation and management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The preoperative history and physical examination for any patient should include the risk factors, signs, and symptoms of liver disease. Routine screening with liver function tests (LFTs) is not recommended. (See <a class="local">'Screening for liver disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nearly every organ system may be affected by liver disease, with implications for perioperative management. (See <a class="local">'Other organ systems'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elective surgery should be postponed for patients with acute viral or alcoholic hepatitis and for patients with acute liver failure  (<a class="graphic graphic_table graphicRef64509" href="/d/graphic/64509.html" rel="external">table 1</a>). (See <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The prothrombin time (PT) and international normalized ratio (INR) are not good predictors of bleeding in patients with liver disease. In anticipation of surgery, we do not routinely transfuse platelets, fresh frozen plasma or cryoprecipitate. For moderate to high risk procedures, we maintain fibrinogen levels ≥150 to 200 mg/dL and platelets of &gt;50,000/microL. (See <a class="local">'Other organ systems'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects of anesthetics on the liver</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anesthetics can affect the liver by reducing hepatic blood flow, or by producing hepatotoxic byproducts.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The currently used volatile anesthetic agents (<a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>) are not associated with hepatotoxicity. Halothane (used outside the United States) should not be administered to patients with liver disease because of the risk of hepatotoxicity, and reduction in cardiac output and hepatic oxygen supply. (See <a class="local">'Effects of anesthetics on the liver'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous (IV) anesthetics do not appear to affect liver function, as long as cardiac output (CO) and blood pressure (BP) are maintained. (See <a class="local">'Effects of anesthetics on the liver'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects of liver disease on pharmacokinetics</strong> – Liver disease can affect the pharmacokinetics of anesthetic drugs by changing drug metabolism, protein binding, and volume of distribution. In general, sedatives and opioids should be administered in small doses and titrated to effect  (<a class="graphic graphic_table graphicRef90196" href="/d/graphic/90196.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benzodiazepines</strong> – The half-life of elimination is increased in patients with liver disease; enhanced sedation and prolonged duration of action should be expected. (See <a class="local">'Sedative hypnotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opioids</strong> – Metabolism may be reduced in patients with liver disease, particularly for <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> and <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>. Elimination of <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> is not appreciably altered in patients with liver disease, unless repeat doses are administered. Elimination and recovery from <a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">remifentanil</a> are unchanged by liver disease. (See <a class="local">'Opioids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuromuscular blocking agents (NMBAs) </strong>–<strong> </strong>Duration of action of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> may be prolonged in patients with liver disease, but rarely to a clinically relevant degree. Clearance, elimination, and duration of action of <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> and <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a> are prolonged in patients with liver disease. Metabolism of <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">atracurium</a> and <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a> are unaffected by liver disease. (See <a class="local">'Neuromuscular blocking agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamic management</strong> – Goals for hemodynamic management include maintenance of hepatic perfusion and, for patients who undergo abdominal surgery, decreased portal pressure with restrictive fluid therapy to minimize bleeding. For patients with ascites or hypoalbuminemia, we administer albumin rather than crystalloids for perioperative volume expansion. (See <a class="local">'Intravenous fluids'</a> above.)</p><p></p><p class="bulletIndent1">Patients with severe liver disease may require higher doses of vasopressors, and may require <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> or <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> to maintain BP. (See <a class="local">'Hemodynamic management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring hemostasis</strong> – During surgery, viscoelastic tests (ie, thromboelastography or thromboelastometry), fibrinogen levels, and platelet count are more useful than the PT/INR for monitoring hemostasis. We maintain a fibrinogen level of ≥150 to 200 mg/dL with administration of cryoprecipitate or <a class="drug drug_general" data-topicid="9082" href="/d/drug information/9082.html" rel="external">fibrinogen concentrate</a>. We also maintain a platelet count ≥50,000/microL for patients who undergo surgery and ≥100,000/microL for active bleeding and during craniotomy. (See <a class="local">'Coagulation management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic resection</strong> – Anesthetic concerns for hepatic resection include the following (see <a class="local">'Anesthesia for hepatic resection'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is always potential for significant hemorrhage. (See <a class="local">'Hemorrhage'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fluid management: The value and necessity of “low CVP” anesthesia and fluid management for reducing blood loss during hepatic resection are unclear despite meta-analyses showing it is safe and effective. We aim for euvolemia, towards hypovolemia, and avoid hypervolemia during hepatic resection. (See <a class="local">'Low central venous pressure anesthesia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postoperative coagulopathy may occur after hepatic resection, and may affect the decision to place an epidural catheter for postoperative pain control because of the risk of spinal epidural hematoma. We offer epidural analgesia when the future liver remnant is predicted to be ≥60 to 70 percent of total liver volume. (See <a class="local">'Coagulopathy and epidural analgesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transhepatic portosystemic shunt (TIPS)</strong> – TIPS may be performed with general anesthesia or monitored anesthesia care. Important anesthetic concerns include the following (see <a class="local">'Anesthesia for transhepatic portosystemic shunt'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who undergo TIPS often have massive ascites and are therefore at risk of aspiration. They may be unable to lie flat.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preoperative volume resuscitation may be required for patients who have had variceal bleeding. If preoperative large volume paracentesis is performed, fluid replacement should include albumin rather than crystalloids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intra-procedure complications of TIPS include vascular injury, hemorrhage, pneumothorax, and dysrhythmia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The increase in venous return to the heart associated with TIPS can unmask cardiac dysfunction or pulmonary hypertension.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Northup PG, Wanamaker RC, Lee VD, et al. Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg 2005; 242:244.</a></li><li><a class="nounderline abstract_t">Teh SH, Nagorney DM, Stevens SR, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology 2007; 132:1261.</a></li><li><a class="nounderline abstract_t">Suman A, Barnes DS, Zein NN, et al. Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol 2004; 2:719.</a></li><li><a class="nounderline abstract_t">Farnsworth N, Fagan SP, Berger DH, Awad SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 2004; 188:580.</a></li><li><a class="nounderline abstract_t">Perkins L, Jeffries M, Patel T. Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis. Clin Gastroenterol Hepatol 2004; 2:1123.</a></li><li><a class="nounderline abstract_t">Befeler AS, Palmer DE, Hoffman M, et al. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch Surg 2005; 140:650.</a></li><li><a class="nounderline abstract_t">Nagai S, Chau LC, Schilke RE, et al. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes. Gastroenterology 2018; 155:1451.</a></li><li><a class="nounderline abstract_t">Mahmud N, Fricker Z, Hubbard RA, et al. Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis. Hepatology 2021; 73:204.</a></li><li><a class="nounderline abstract_t">Kim SY, Yim HJ, Park SM, et al. Validation of a Mayo post-operative mortality risk prediction model in Korean cirrhotic patients. Liver Int 2011; 31:222.</a></li><li><a class="nounderline abstract_t">Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56:539.</a></li><li><a class="nounderline abstract_t">Theocharidou E, Krag A, Bendtsen F, et al. Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis. Liver Int 2012; 32:1327.</a></li><li><a class="nounderline abstract_t">Alkhouri N, Tamimi TA, Yerian L, et al. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci 2010; 55:2644.</a></li><li><a class="nounderline abstract_t">Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49:225.</a></li><li><a class="nounderline abstract_t">Petta S, Maida M, Macaluso FS, et al. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology 2016; 150:145.</a></li><li><a class="nounderline abstract_t">Klinge M, Coppler T, Liebschutz JM, et al. The assessment and management of pain in cirrhosis. Curr Hepatol Rep 2018; 17:42.</a></li><li><a class="nounderline abstract_t">Rogal SS, Winger D, Bielefeldt K, Szigethy E. Pain and opioid use in chronic liver disease. Dig Dis Sci 2013; 58:2976.</a></li><li><a class="nounderline abstract_t">Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018; 11:135.</a></li><li><a class="nounderline abstract_t">Rogal SS, Bielefeldt K, Wasan AD, et al. Fibromyalgia symptoms and cirrhosis. Dig Dis Sci 2015; 60:1482.</a></li><li><a class="nounderline abstract_t">Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44:440.</a></li><li><a class="nounderline abstract_t">Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 2017; 34:332.</a></li><li><a class="nounderline abstract_t">Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care 2016; 20:100.</a></li><li><a class="nounderline abstract_t">Nadim MK, Durand F, Kellum JA, et al. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol 2016; 64:717.</a></li><li><a class="nounderline abstract_t">Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17:R76.</a></li><li><a class="nounderline abstract_t">Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008; 134:172.</a></li><li><a class="nounderline abstract_t">Niemann CU, Feiner J, Behrends M, et al. Central venous pressure monitoring during living right donor hepatectomy. Liver Transpl 2007; 13:266.</a></li><li><a class="nounderline abstract_t">Myo Bui CC, Worapot A, Xia W, et al. Gastroesophageal and hemorrhagic complications associated with intraoperative transesophageal echocardiography in patients with model for end-stage liver disease score 25 or higher. J Cardiothorac Vasc Anesth 2015; 29:594.</a></li><li><a class="nounderline abstract_t">Markin NW, Sharma A, Grant W, Shillcutt SK. The safety of transesophageal echocardiography in patients undergoing orthotopic liver transplantation. J Cardiothorac Vasc Anesth 2015; 29:588.</a></li><li><a class="nounderline abstract_t">Spier BJ, Larue SJ, Teelin TC, et al. Review of complications in a series of patients with known gastro-esophageal varices undergoing transesophageal echocardiography. J Am Soc Echocardiogr 2009; 22:396.</a></li><li><a class="nounderline abstract_t">Kennedy WF Jr, Everett GB, Cobb LA, Allen GD. Simultaneous systemic and hepatic hemodynamic measurements during high peridural anesthesia in normal man. Anesth Analg 1971; 50:1069.</a></li><li><a class="nounderline abstract_t">Meierhenrich R, Wagner F, Schütz W, et al. The effects of thoracic epidural anesthesia on hepatic blood flow in patients under general anesthesia. Anesth Analg 2009; 108:1331.</a></li><li><a class="nounderline abstract_t">Tanaka N, Nagata N, Hamakawa T, Takasaki M. The effect of dopamine on hepatic blood flow in patients undergoing epidural anesthesia. Anesth Analg 1997; 85:286.</a></li><li><a class="nounderline abstract_t">McDonnell JG, O'Donnell B, Curley G, et al. The analgesic efficacy of transversus abdominis plane block after abdominal surgery: a prospective randomized controlled trial. Anesth Analg 2007; 104:193.</a></li><li><a class="nounderline abstract_t">Frink EJ Jr. The hepatic effects of sevoflurane. Anesth Analg 1995; 81:S46.</a></li><li><a class="nounderline abstract_t">Schindler E, Müller M, Zickmann B, et al. [Blood supply to the liver in the human after 1 MAC desflurane in comparison with isoflurane and halothane]. Anasthesiol Intensivmed Notfallmed Schmerzther 1996; 31:344.</a></li><li><a class="nounderline abstract_t">Gelman S, Dillard E, Bradley EL Jr. Hepatic circulation during surgical stress and anesthesia with halothane, isoflurane, or fentanyl. Anesth Analg 1987; 66:936.</a></li><li><a class="nounderline abstract_t">Njoku D, Laster MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997; 84:173.</a></li><li><a class="nounderline abstract_t">Obata R, Bito H, Ohmura M, et al. The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function. Anesth Analg 2000; 91:1262.</a></li><li><a class="nounderline abstract_t">Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43:618.</a></li><li><a class="nounderline abstract_t">Nunn JF. Clinical aspects of the interaction between nitrous oxide and vitamin B12. Br J Anaesth 1987; 59:3.</a></li><li><a class="nounderline abstract_t">Sesso RM, Iunes Y, Melo AC. Myeloneuropathy following nitrous oxide anesthaesia in a patient with macrocytic anaemia. Neuroradiology 1999; 41:588.</a></li><li><a class="nounderline abstract_t">Hadzic A, Glab K, Sanborn KV, Thys DM. Severe neurologic deficit after nitrous oxide anesthesia. Anesthesiology 1995; 83:863.</a></li><li><a class="nounderline abstract_t">Servin F, Desmonts JM, Haberer JP, et al. Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology 1988; 69:887.</a></li><li><a class="nounderline abstract_t">Duvaldestin P, Chauvin M, Lebrault C, et al. Effect of upper abdominal surgery and cirrhosis upon the pharmacokinetics of methohexital. Acta Anaesthesiol Scand 1991; 35:159.</a></li><li><a class="nounderline abstract_t">Pandele G, Chaux F, Salvadori C, et al. Thiopental pharmacokinetics in patients with cirrhosis. Anesthesiology 1983; 59:123.</a></li><li><a class="nounderline abstract_t">van Beem H, Manger FW, van Boxtel C, van Bentem N. Etomidate anaesthesia in patients with cirrhosis of the liver: pharmacokinetic data. Anaesthesia 1983; 38 Suppl:61.</a></li><li><a class="nounderline abstract_t">Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301:489.</a></li><li><a class="nounderline abstract_t">Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37:17.</a></li><li><a class="nounderline abstract_t">Klotz U, McHorse TS, Wilkinson GR, Schenker S. The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther 1974; 16:667.</a></li><li><a class="nounderline abstract_t">Pond SM, Tong T, Benowitz NL, et al. Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther 1981; 30:183.</a></li><li><a class="nounderline abstract_t">Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 1996; 84:812.</a></li><li><a class="nounderline abstract_t">Navapurkar VU, Archer S, Gupta SK, et al. Metabolism of remifentanil during liver transplantation. Br J Anaesth 1998; 81:881.</a></li><li><a class="nounderline abstract_t">Adams DR, Tollinche LE, Yeoh CB, et al. Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study. Anaesthesia 2020; 75:348.</a></li><li><a class="nounderline abstract_t">Thomas SD, Boyd AH. Prolonged neuromuscular block associated with acute fatty liver of pregnancy and reduced plasma cholinesterase. Eur J Anaesthesiol 1994; 11:245.</a></li><li><a class="nounderline abstract_t">Viby-Mogensen J, Hanel HK. Prolonged apnoea after suxamethonium: an analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit. Acta Anaesthesiol Scand 1978; 22:371.</a></li><li><a class="nounderline abstract_t">Cook DR, Freeman JA, Lai AA, et al. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br J Anaesth 1992; 69:580.</a></li><li><a class="nounderline abstract_t">Devlin JC, Head-Rapson AG, Parker CJ, Hunter JM. Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis. Br J Anaesth 1993; 71:227.</a></li><li><a class="nounderline abstract_t">Hunter JM, Parker CJ, Bell CF, et al. The use of different doses of vecuronium in patients with liver dysfunction. Br J Anaesth 1985; 57:758.</a></li><li><a class="nounderline abstract_t">Magorian T, Wood P, Caldwell J, et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 1995; 80:754.</a></li><li><a class="nounderline abstract_t">De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996; 76:624.</a></li><li><a class="nounderline abstract_t">Ward S, Neill EA. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth 1983; 55:1169.</a></li><li><a class="nounderline abstract_t">Møller S, Henriksen JH. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998; 58:361.</a></li><li><a class="nounderline abstract_t">Wagener G, Kovalevskaya G, Minhaz M, et al. Vasopressin deficiency and vasodilatory state in end-stage liver disease. J Cardiothorac Vasc Anesth 2011; 25:665.</a></li><li><a class="nounderline abstract_t">Alves de Mattos A. Current indications for the use of albumin in the treatment of cirrhosis. Ann Hepatol 2011; 10 Suppl 1:S15.</a></li><li><a class="nounderline abstract_t">Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol 2014; 4:302.</a></li><li><a class="nounderline abstract_t">Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087.</a></li><li><a class="nounderline abstract_t">Terg R, Gadano A, Cartier M, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int 2009; 29:415.</a></li><li><a class="nounderline abstract_t">Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol 2009; 15:67.</a></li><li><a class="nounderline abstract_t">Evans C, Evans M, Pollock AV. The incidence and causes of postoperative jaundice. A prospective study. Br J Anaesth 1974; 46:520.</a></li><li><a class="nounderline abstract_t">Suttner SW, Schmidt CC, Boldt J, et al. Low-flow desflurane and sevoflurane anesthesia minimally affect hepatic integrity and function in elderly patients. Anesth Analg 2000; 91:206.</a></li><li><a class="nounderline abstract_t">Lentschener C, Benhamou D, Mercier FJ, et al. Aprotinin reduces blood loss in patients undergoing elective liver resection. Anesth Analg 1997; 84:875.</a></li><li><a class="nounderline abstract_t">Jones RM, Moulton CE, Hardy KJ. Central venous pressure and its effect on blood loss during liver resection. Br J Surg 1998; 85:1058.</a></li><li><a class="nounderline abstract_t">The administration of blood and blood components and the management of transfused patients. British Committee for Standards in Haematology, Blood Transfusion Task Force. Royal College of Nursing and the Royal College of Surgeons of England. Transfus Med 1999; 9:227.</a></li><li><a class="nounderline abstract_t">Kim YK, Chin JH, Kang SJ, et al. Association between central venous pressure and blood loss during hepatic resection in 984 living donors. Acta Anaesthesiol Scand 2009; 53:601.</a></li><li><a class="nounderline abstract_t">Chhibber A, Dziak J, Kolano J, et al. Anesthesia care for adult live donor hepatectomy: our experiences with 100 cases. Liver Transpl 2007; 13:537.</a></li><li><a class="nounderline abstract_t">Liu TS, Shen QH, Zhou XY, et al. Application of controlled low central venous pressure during hepatectomy: A systematic review and meta-analysis. J Clin Anesth 2021; 75:110467.</a></li><li><a class="nounderline abstract_t">Sand L, Rizell M, Houltz E, et al. Effect of patient position and PEEP on hepatic, portal and central venous pressures during liver resection. Acta Anaesthesiol Scand 2011; 55:1106.</a></li><li><a class="nounderline abstract_t">Torzilli G, Procopio F, Donadon M, et al. Safety of intermittent Pringle maneuver cumulative time exceeding 120 minutes in liver resection: a further step in favor of the "radical but conservative" policy. Ann Surg 2012; 255:270.</a></li><li><a class="nounderline abstract_t">Bismuth H, Castaing D, Garden OJ. Major hepatic resection under total vascular exclusion. Ann Surg 1989; 210:13.</a></li><li><a class="nounderline abstract_t">Matot I, Scheinin O, Eid A, Jurim O. Epidural anesthesia and analgesia in liver resection. Anesth Analg 2002; 95:1179.</a></li><li><a class="nounderline abstract_t">Borromeo CJ, Stix MS, Lally A, Pomfret EA. Epidural catheter and increased prothrombin time after right lobe hepatectomy for living donor transplantation. Anesth Analg 2000; 91:1139.</a></li><li><a class="nounderline abstract_t">Bell R, Ward D, Jeffery J, et al. A Randomized Controlled Trial Comparing Epidural Analgesia Versus Continuous Local Anesthetic Infiltration Via Abdominal Wound Catheter in Open Liver Resection. Ann Surg 2019; 269:413.</a></li></ol></div><div id="topicVersionRevision">Topic 91242 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16041215" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17408652" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk factors for mortality after surgery in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15290666" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546574" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625658" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027329" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30056096" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32939786" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134111" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Validation of a Mayo post-operative mortality risk prediction model in Korean cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688208" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cirrhotic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22292920" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19960252" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508169" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hepatitis C virus infection and the risk of coronary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26386298" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29552453" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The assessment and management of pain in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23512406" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pain and opioid use in chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30992804" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pain management in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25433921" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fibromyalgia symptoms and cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871542" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Thrombin generation in patients with cirrhosis: the role of platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28459785" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27072503" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26519602" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Management of the critically ill patient with cirrhosis: A multidisciplinary perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23601765" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Management of bleeding and coagulopathy following major trauma: an updated European guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18628220" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17256757" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Central venous pressure monitoring during living right donor hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25661642" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gastroesophageal and hemorrhagic complications associated with intraoperative transesophageal echocardiography in patients with model for end-stage liver disease score 25 or higher.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25622974" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The safety of transesophageal echocardiography in patients undergoing orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231133" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Review of complications in a series of patients with known gastro-esophageal varices undergoing transesophageal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5166895" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Simultaneous systemic and hepatic hemodynamic measurements during high peridural anesthesia in normal man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299808" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The effects of thoracic epidural anesthesia on hepatic blood flow in patients under general anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9249101" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of dopamine on hepatic blood flow in patients undergoing epidural anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17179269" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The analgesic efficacy of transversus abdominis plane block after abdominal surgery: a prospective randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486148" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The hepatic effects of sevoflurane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8962928" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : [Blood supply to the liver in the human after 1 MAC desflurane in comparison with isoflurane and halothane].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3307530" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hepatic circulation during surgical stress and anesthesia with halothane, isoflurane, or fentanyl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989020" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049919" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16496329" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Drug-induced liver injury: summary of a single topic clinical research conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3548788" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical aspects of the interaction between nitrous oxide and vitamin B12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10447571" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Myeloneuropathy following nitrous oxide anesthaesia in a patient with macrocytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7574068" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Severe neurologic deficit after nitrous oxide anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3264120" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pharmacokinetics and protein binding of propofol in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024566" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of upper abdominal surgery and cirrhosis upon the pharmacokinetics of methohexital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6869869" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Thiopental pharmacokinetics in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6869758" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Etomidate anaesthesia in patients with cirrhosis of the liver: pharmacokinetic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188334" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451781" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pharmacokinetics of opioids in liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4419525" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effect of cirrhosis on the disposition and elimination of meperidine in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7249503" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8638835" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10211013" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Metabolism of remifentanil during liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31721151" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8050430" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prolonged neuromuscular block associated with acute fatty liver of pregnancy and reduced plasma cholinesterase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/726855" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prolonged apnoea after suxamethonium: an analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1334687" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8123397" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2861836" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The use of different doses of vecuronium in patients with liver dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7893030" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8688259" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6689126" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9819185" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Neurohumoral fluid regulation in chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21126886" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Vasopressin deficiency and vasodilatory state in end-stage liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21566250" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Current indications for the use of albumin in the treatment of cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25755577" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Role of human albumin in the management of complications of liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19475696" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Management of adult patients with ascites due to cirrhosis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18803587" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19115470" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Evaluation and management of patients with refractory ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4458773" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The incidence and causes of postoperative jaundice. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10866914" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Low-flow desflurane and sevoflurane anesthesia minimally affect hepatic integrity and function in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9085974" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Aprotinin reduces blood loss in patients undergoing elective liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9717995" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Central venous pressure and its effect on blood loss during liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555817" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The administration of blood and blood components and the management of transfused patients. British Committee for Standards in Haematology, Blood Transfusion Task Force. Royal College of Nursing and the Royal College of Surgeons of England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19419353" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Association between central venous pressure and blood loss during hepatic resection in 984 living donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17394151" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Anesthesia care for adult live donor hepatectomy: our experiences with 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34343737" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Application of controlled low central venous pressure during hepatectomy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092208" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of patient position and PEEP on hepatic, portal and central venous pressures during liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975322" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Safety of intermittent Pringle maneuver cumulative time exceeding 120 minutes in liver resection: a further step in favor of the "radical but conservative" policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2742411" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Major hepatic resection under total vascular exclusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401587" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Epidural anesthesia and analgesia in liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049898" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Epidural catheter and increased prothrombin time after right lobe hepatectomy for living donor transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30080727" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A Randomized Controlled Trial Comparing Epidural Analgesia Versus Continuous Local Anesthetic Infiltration Via Abdominal Wound Catheter in Open Liver Resection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
